inno.N

Mar. 12, 2020

K-CAB, a new drug for GERD, helicobacter pylori eradication indication added
- Fourth indication following treatment for ERD, NERD and gastric ulcer

K-CAB Tab., a new drug for gastroesophageal reflux disease, can also be used to treat helicobacter pylori eradication.

CJ HealthCare (CEO Kang, Seok - Hee), a subsidiary Kolmar Korea, recently announced that it has been approved by the Ministry of Food and Drug Safety for the additional indication of K-CAB Tab. (ingredient: tegoprazan). The newly added indication is 'an antibiotic combination therapy for the eradication of Helicobacter pylori in patients with peptic ulcer and/or chronic atrophic gastritis.'

K-CAB Tab. secured four indications ranging from ERD, NERD and gastric ulcer treatment to helicobacter pylori eradication, further expanding the treatment area of digestive system diseases. In particular, K-CAB Tab. is the first product in Korea to obtain indications for the treatment of eradication in patients with chronic atrophic gastritis.

K-CAB Tab.  is a new type of potassium competitive acid blocker (P-CAB).

K-CAB Tab. is Korea's No. 30 new drug for GERD, launched in March 2019. It is characterized by its fast drug efficacy compared to conventional treatments, its ability to be taken before and after meals, and the suppression of gastric acid secretion at night due to its excellent drug lasting power.

Helicobacter pylori (Helicobacter pylori or H. pylori) is known to cause chronic gastritis, gastric ulcer, duodenal ulcer, gastric adenocarcinoma, gastric lymphoma, etc., mainly due to infection of the gastrointestinal mucosa.

In this permission of K-CAB Tab., 50mgs of K-CAB tab., 1 gram of amoxicillin, and 500 mgs of clarithromycin are used twice a day for 7 days for the treatment of Helicobacter pylori bacteriostasis.

K-CAB Tab. can be prescribed at the patient's own expense for helicobacter pylori eradication from the 9th of this month, following the treatment of the previously approved gastric ulcer, and the insurance benefit will be expanded sequentially. CJ HealthCare is working to secure additional indications of K-CAB Tab, such as maintenance therapy after treatment of GERD, and prevention of gastroduodenal ulcer caused by nonsteroidal antiinflammatory drugs and is also actively conducting differentiated clinical research activities to increase product competitiveness.